Hepatitis C and Hepatocellular Cancer: To Treat or Not to Treat.
作者信息
Dhanasekaran Renumathy, Kwo Paul Y
机构信息
Division of Gastroenterology and Hepatology Stanford University Palo Alto CA.
出版信息
Clin Liver Dis (Hoboken). 2021 Apr 13;17(3):169-173. doi: 10.1002/cld.1003. eCollection 2021 Mar.
Abstract
摘要
相似文献
1
Hepatitis C and Hepatocellular Cancer: To Treat or Not to Treat.丙型肝炎与肝细胞癌：治疗与否
Clin Liver Dis (Hoboken). 2021 Apr 13;17(3):169-173. doi: 10.1002/cld.1003. eCollection 2021 Mar.
2
Identification and screening of 416 patients with chronic hepatitis at high risk to develop hepatocellular cancer.对416例有发展为肝细胞癌高风险的慢性肝炎患者进行识别与筛查。
Ann Surg. 1995 Sep;222(3):375-80; discussion 380-3. doi: 10.1097/00000658-199509000-00014.
3
[Assessment of external risk factors of hepatocellular cancer development and markers of genetic predisposition to its development in the ethnic group of yakut - men].[雅库特族男性肝细胞癌发生的外部风险因素及其发生遗传易感性标志物的评估]
Ter Arkh. 2020 Jan 15;92(1):56-61. doi: 10.26442/00403660.2020.01.000505.
4
Detection of mutant p53 in hepatocellular cancer from Turkey and its correlation with clinicopathologic parameters.土耳其肝细胞癌中突变型p53的检测及其与临床病理参数的相关性。
Dig Dis Sci. 2003 May;48(5):865-9. doi: 10.1023/a:1023031008757.
5
Effect of the etiology of viral cirrhosis on the survival of patients with hepatocellular carcinoma.病毒性肝硬化病因对肝细胞癌患者生存的影响。
Am J Gastroenterol. 2006 Jan;101(1):91-8. doi: 10.1111/j.1572-0241.2006.00364.x.
6
Prevalence of antibodies to hepatitis C virus in patients with hepatocellular carcinoma in Austria.奥地利肝细胞癌患者中丙型肝炎病毒抗体的流行情况。
Arch Virol Suppl. 1992;4:76-80. doi: 10.1007/978-3-7091-5633-9_16.
7
TCR gene-modified T cells can efficiently treat established hepatitis C-associated hepatocellular carcinoma tumors.T细胞受体基因修饰的T细胞能够有效治疗已形成的丙型肝炎相关肝细胞癌肿瘤。
Cancer Immunol Immunother. 2016 Mar;65(3):293-304. doi: 10.1007/s00262-016-1800-2. Epub 2016 Feb 3.
8
Viral pathogenesis of hepatocellular carcinoma in the United States.美国肝细胞癌的病毒发病机制
Hepatology. 1993 Dec;18(6):1326-33.
9
Hepatocellular carcinoma.肝细胞癌
Curr Opin Gastroenterol. 1999 May;15(3):253-9. doi: 10.1097/00001574-199905000-00011.
10
Preparing the patient for success: treat or wait?为成功做好准备：治疗还是等待？
Dig Liver Dis. 2013 Sep 30;45 Suppl 5:S332-6. doi: 10.1016/j.dld.2013.07.013.
引用本文的文献
1
Meeting the challenges of hepatocellular carcinoma post sustained virologic response in the post-direct- acting antiviral era: A path forward: Editorial on "Unmet needs in the post-direct-acting antivirals era: The risk and molecular mechanisms of hepatocellular carcinoma after hepatitis C virus eradication".直面直接抗病毒药物时代持续病毒学应答后肝细胞癌的挑战：前进之路：关于“直接抗病毒药物时代未满足的需求：丙型肝炎病毒根除后肝细胞癌的风险及分子机制”的社论
Clin Mol Hepatol. 2024 Oct;30(4):677-681. doi: 10.3350/cmh.2024.0418. Epub 2024 Jun 11.
2
Global burden of primary liver cancer and its association with underlying aetiologies, sociodemographic status, and sex differences from 1990-2019: A DALY-based analysis of the Global Burden of Disease 2019 study.全球原发性肝癌负担及其与潜在病因、社会人口地位和性别差异的关系：基于残疾调整生命年的 2019 年全球疾病负担研究分析。
Clin Mol Hepatol. 2023 Apr;29(2):433-452. doi: 10.3350/cmh.2022.0316. Epub 2023 Jan 4.
3
Immune Microenvironment and Immunotherapeutic Management in Virus-Associated Digestive System Tumors.病毒相关性消化系统肿瘤的免疫微环境与免疫治疗管理。
Int J Mol Sci. 2022 Nov 6;23(21):13612. doi: 10.3390/ijms232113612.
本文引用的文献
1
Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Is Associated With Increased Survival in Patients With a History of Hepatocellular Carcinoma.直接作用抗病毒疗法治疗丙型肝炎病毒感染与肝癌病史患者的生存获益增加相关。
Gastroenterology. 2019 Nov;157(5):1253-1263.e2. doi: 10.1053/j.gastro.2019.07.040. Epub 2019 Jul 30.
2
Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs.在纳入监测项目的肝硬化患者中，直接抗病毒治疗 HCV 后肝细胞癌的发生率。
Gastroenterology. 2018 Nov;155(5):1436-1450.e6. doi: 10.1053/j.gastro.2018.07.015. Epub 2018 Jul 19.
3
HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma.直接作用抗病毒药物诱导的丙型肝炎病毒清除可降低肝细胞癌的风险。
J Hepatol. 2017 Sep 5. doi: 10.1016/j.jhep.2017.08.030.
4
Impact of Sustained Virologic Response with Direct-Acting Antiviral Treatment on Mortality in Patients with Advanced Liver Disease.直接作用抗病毒治疗的持续病毒学应答对晚期肝病患者死亡率的影响。
Hepatology. 2019 Feb;69(2):487-497. doi: 10.1002/hep.29408. Epub 2018 May 15.
5
Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents.直接作用抗病毒药物治疗的 HCV 患者的肝细胞癌风险。
Gastroenterology. 2017 Oct;153(4):996-1005.e1. doi: 10.1053/j.gastro.2017.06.012. Epub 2017 Jun 19.
6
Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals.肝细胞癌会降低使用直接作用抗病毒药物成功治疗丙型肝炎病毒的几率。
J Hepatol. 2017 Jun;66(6):1173-1181. doi: 10.1016/j.jhep.2017.01.020. Epub 2017 Feb 2.
7
Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals.直接作用抗病毒药物治疗的丙型肝炎相关肝硬化中肝细胞癌的早期发生和复发。
J Hepatol. 2016 Oct;65(4):727-733. doi: 10.1016/j.jhep.2016.06.015. Epub 2016 Jun 24.
8
Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy.接受无干扰素治疗的丙型肝炎相关 HCC 患者早期肿瘤复发率高。
J Hepatol. 2016 Oct;65(4):719-726. doi: 10.1016/j.jhep.2016.04.008. Epub 2016 Apr 13.
9
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.索拉非尼辅助治疗肝细胞癌切除术后或消融后（STORM）：一项 3 期、随机、双盲、安慰剂对照试验。
Lancet Oncol. 2015 Oct;16(13):1344-54. doi: 10.1016/S1470-2045(15)00198-9. Epub 2015 Sep 8.
10
Tumor suppressors, chromosomal instability, and hepatitis C virus-associated liver cancer.肿瘤抑制因子、染色体不稳定与丙型肝炎病毒相关肝癌
Annu Rev Pathol. 2009;4:399-415. doi: 10.1146/annurev.pathol.4.110807.092202.
Zotero 插件